Skip to main content

Table 4 Univariate and multivariate analysis of favorable factors for postoperative prognosis in patients with moderate to severe AFL

From: Prognostic and functional impact of perioperative LAMA/LABA inhaled therapy in patients with lung cancer and chronic obstructive pulmonary disease

Clinicopathologic variable Univariate analysis Multivariate analysis
RR 95%CI p value RR 95%CI p value
A. Analysis of favorable factors for overall survival
Age (< 75 year) 0.88 0.29–2.25 0.798
Histology:    0.083
 Squamous cell carcinoma 1.00 Reference  
 Adenocarcinoma 0.47 0.18–1.14 0.094
 Other 0.18 0.01–1.01 0.051
Lymph node metastasis (absent) 0.61 0.26–1.55 0.290
Pathologic stage:    0.027    0.106
 I 1.00 Reference   1.00 Reference  
 II 2.96 0.99–8.25 0.052 2.14 0.70–6.16 0.176
 III 3.66 1.20–10.49 0.024 3.11 1.00–9.13 0.107
Bronchodilator    0.010    0.048
 LAMA/LABA 1.00 Reference   1.00 Reference  
 LAMA or No-BD 4.16 1.37–11.1   3.21 1.01–14.20  
B. Analysis of favorable factors for disease-free survival
Age (< 75 year) 0.59 0.69–5.12 0.266
Histology:    0.038    0.350
 Squamous cell carcinoma 1.00 Reference   1.00 Reference  
 Adenocarcinoma 0.42 0.17–0.96 0.040 0.68 0.23–2.05 0.311
 Other 0.16 0.01–0.90 0.035 0.23 0.01–1.59 0.148
Lymph node metastasis (absent) 0.49 0.22–1.13 0.091
Pathologic stage    0.007    0.233
 I 1.00 Reference   1.00 Reference  
 II 3.21 1.18–8.17 0.024 1.35 0.39–4.90 0.635
 III 4.13 1.47–11.0 0.009 2.70 0.83–8.37 0.278
Bronchodilator    0.003    0.018
 LAMA/LABA 1.00 Reference   1.00 Reference  
 LAMA or No-BD 3.90 1.55–11.8   3.29 1.22–10.43 0.120
  1. COPD chronic obstructive pulmonary disease; LAMA long-acting muscarinic antagonists; LABA long-acting β2-agonists; BD bronchodilator; RR relative risk; CI confidence interval